Discovery of potential therapeutic targets for non-small cell lung cancer using high-throughput metabolomics analysis based on liquid chromatography coupled with tandem mass spectrometry

被引:6
|
作者
Xu, Hong-dan [1 ]
Luo, Wen [2 ]
Lin, Yuanlong [3 ]
Zhang, Jiawen [2 ]
Zhang, Lijuan [2 ]
Zhang, Wei [2 ]
Huang, Shu-ming [4 ]
机构
[1] Heilongjiang Univ Chinese Med, Coll Jiamusi, Jiamusi 154007, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care, Harbin 150081, Heilongjiang, Peoples R China
[3] Harbin Med Univ, Affiliated Hosp 4, Infect Dis Dept, Harbin, Heilongjiang, Peoples R China
[4] Heilongjiang Univ Med Chinese, Inst Chinese Med, Heping Rd 24, Harbin 150040, Heilongjiang, Peoples R China
关键词
SERUM; PATHWAYS; STRATEGY; RISK;
D O I
10.1039/c9ra00987f
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Lung cancer is a severe health problem and threatens a patient's quality of life. The metabolites present in biological systems are expected to be key mediators and the changes in these metabolites play an important role in promoting health. Metabolomics can unravel the global metabolic changes and identify significant biological pathways involved in disease development. However, the role of metabolites in lung cancer is still largely unknown. In the present study, we developed a liquid chromatography coupled with tandem mass spectrometry method for biomarker discovery and identification of non-small cell lung cancer (NSCLC) from metabolomics data sets and aimed to investigate the metabolic profiles of NSCLC samples to identify potential disease biomarkers and to reveal the pathological mechanism. After cell metabolite extraction, the metabolic changes in NSCLC cells were characterized and targeted metabolite analysis was adopted to offer a novel opportunity to probe into the relationship between differentially regulated cell metabolites and NSCLC. Quantitative analysis of key enzymes in the disturbed pathways by proteomics was employed to verify metabolomic pathway changes. A total of 13 specific biomarkers were identified in NSCLC cells related with metabolic disturbance of NSCLC morbidity, which were involved in 4 vital pathways, namely glycine, serine and threonine metabolism, aminoacyl-tRNA biosynthesis, tyrosine metabolism and sphingolipid metabolism. The proteomics analysis illustrated the obvious fluctuation of the expression of the key enzymes in these pathways, including the downregulation of 3-phosphoglycerate dehydrogenase, phosphoserine phosphatase, tyrosinase and argininosuccinic acid catenase. NSCLC occurrence is mainly related to amino acid and fatty acid metabolic alteration. These findings highlight that the metabolome can provide information on the molecular profiles of cells, which can aid in investigating the metabolite changes to reveal the pathological mechanism.
引用
收藏
页码:10905 / 10913
页数:9
相关论文
共 50 条
  • [41] A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition
    Castro-Perez, J
    Plumb, R
    Liang, L
    Yang, E
    RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2005, 19 (06) : 798 - 804
  • [42] The Detection and Analysis of RET Gene Fusion in Non-Small Lung Cancer in High-Throughput Sequencing
    Niu, L.
    Xu, Z.
    Chen, F.
    Yang, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2379 - S2379
  • [43] High-throughput Molecular Genotyping for Small Biopsy Samples in Advanced Non-small Cell Lung Cancer Patients
    Maeng, Chi Hoon
    Lee, Ho Yun
    Kim, Young Wook
    Choi, Moon Ki
    Hong, Jung Yong
    Jung, Hyun Ae
    Lee, Kyung Soo
    Kim, Hojoong
    Kwon, O. Jung
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Um, Sang-Won
    Ahn, Myung-Ju
    ANTICANCER RESEARCH, 2013, 33 (11) : 5127 - 5133
  • [44] Long non-coding RNAs as potential therapeutic targets in non-small cell lung cancer (Review)
    Tang, Peiyu
    Sun, Dejuan
    Xu, Wei
    Li, Hua
    Chen, Lixia
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2023, 52 (02)
  • [45] Lung Cancer Serum Biomarker Discovery Using Label-Free Liquid Chromatography-Tandem Mass Spectrometry
    Zeng, Xuemei
    Hood, Brian L.
    Zhao, Ting
    Conrads, Thomas P.
    Sun, Mai
    Gopalakrishnan, Vanathi
    Grover, Himanshu
    Day, Roger S.
    Weissfeld, Joel L.
    Wilson, David O.
    Siegfried, Jill M.
    Bigbee, William L.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) : 725 - 734
  • [46] Integrative Analysis for Identification of Therapeutic Targets and Prognostic Signatures in Non-Small Cell Lung Cancer
    Erkin, Ozgur Cem
    Comertpay, Betul
    Gov, Esra
    BIOINFORMATICS AND BIOLOGY INSIGHTS, 2022, 16
  • [47] Development of a high-throughput assay for aldosterone synthase inhibitors using high-performance liquid chromatography-tandem mass spectrometry
    Yurek, David
    Yu, Lan
    Schrementi, James
    Bell, Michael G.
    McGee, James
    Kowala, Mark
    Kuo, Ming-shang
    Wang, Jian
    ANALYTICAL BIOCHEMISTRY, 2014, 462 : 44 - 50
  • [48] Integrative Analysis for Identification of Therapeutic Targets and Prognostic Signatures in Non-Small Cell Lung Cancer
    Erkin, Ozgur Cem
    Comertpay, Betul
    Gov, Esra
    BIOINFORMATICS AND BIOLOGY INSIGHTS, 2022, 16
  • [49] Preliminary Screening of Capsaicin-based Compounds as Potential Therapeutic Targets for Human Non-small Cell Lung Cancer
    Weidman, Cory
    Wallert, Mark A.
    Provost, Joseph J.
    FASEB JOURNAL, 2010, 24
  • [50] High-throughput analysis of ramelteon, agomelatine, and melatonin in human plasma by ultra-performance liquid chromatography–tandem mass spectrometry
    Tadashi Ogawa
    Masae Iwai
    Hideki Hattori
    Kei Zaitsu
    Takeshi Kumazawa
    Akira Ishii
    Osamu Suzuki
    Hiroshi Seno
    Forensic Toxicology, 2014, 32 : 126 - 131